NeuroPsy InfoHub adună studii și articole verificate editorial despre sănătate mintală și afecțiuni neurologice — pentru pacienți, familii și specialiști.
Research identifies Arc, a native brain protein, as a mediator of toxic tau spread between neurons via extracellular vesicles in Alzheimer's disease. While Arc enables sick neurons to survive longer by expelling tau aggregates, it also paradoxically promotes pathology transmission to healthy cells, suggesting the extracellular space as a potential therapeutic intervention point.
This review examines the relationship between loneliness and social isolation as major risk factors for Alzheimer's disease and cognitive decline, with particular attention to sex differences. The authors discuss mechanisms linking isolation to AD pathology and propose approaches for developing prevention and treatment strategies based on understanding these associations.
Researchers developed a tablet-based software application designed to slow cognitive and communicative decline in individuals with Alzheimer's disease for home use. A randomized controlled trial with 32 participants (mild, moderate, and severe stages) compared outcomes between those using the application plus pharmacological treatment versus pharmacological treatment alone.
This health economics study examines costs associated with using neuroimaging (PET and MRI) to identify Alzheimer's disease patients most likely to benefit from lecanemab treatment over three years. The authors highlight a critical concern: approximately 78% of patients with mild cognitive impairment do not progress to dementia, making prophylactic treatment in all MCI patients costly and ethically problematic; they identify combined fluorodeoxyglucose and MRI imaging as the most cost-efficient approach at $177,000 per positive outcome with adjusted lecanemab pricing.
This study examined whether plasma levels of ergothioneine and its metabolite hercynine correlate with resistance to cognitive decline in older dementia-free individuals with Alzheimer's amyloid pathology. Higher ergothioneine metabolism (HC:ET ratio) attenuated the relationship between amyloid biomarkers and cognitive decline, suggesting ergothioneine's potential neuroprotective role warrants further investigation.
